October 25: The Week in Cancer News
Asian American and Pacific Islander women face rising rates of early-onset breast cancer, and the risk for dying of COVID-19 is twice as high in people living with cancer.
Progress Against Cancer
Asian American and Pacific Islander women face rising rates of early-onset breast cancer, and the risk for dying of COVID-19 is twice as high in people living with cancer.
Animals with longer gestation times may have fewer cancers, but the way traits relate to cancer risk is complex. Cancer occurs in animals as well as in humans, at widely varying rates among different...
The FDA approved the claudin 18.2-targeted therapy Zolbetuximab-clzb for some gastric and gastroesophageal junction cancers. The U.S. Food and Drug Administration (FDA) has approved zolbetuximab-clzb (Vyloy) plus a chemotherapy regimen consisting of fluoropyrimidine- and platinum-containing...
Immunotherapy lowers risk of side effects in advanced lymphoma, and an extra course of chemotherapy improves survival in cervical cancer.
Expanded dependent coverage improves cancer outcomes in young adults, and breast cancer treatment can lead to faster cell aging.
The PI3K inhibitor is approved as part of combination therapy for certain patients whose breast cancer recurred on or after endocrine therapy. The U.S. Food and Drug Administration (FDA) approved inavolisib (Itovebi), in combination...
Study finds people who receive brain radiation often recover cognitive abilities over time, and report details breast cancer trends.
The immunotherapy is now approved to treat certain lung cancers before and after surgery. The U.S. Food and Drug Administration (FDA) has approved neoadjuvant nivolumab (Opdivo) with platinum-containing chemotherapy, followed by adjuvant nivolumab alone,...
Adding MRI to prostate screening can help limit overdiagnosis, and breast cancer patients who smoke have a higher risk of radiotherapy-related lung cancer.
The accelerated approval of selpercatinib for certain patients with thyroid cancer was converted to a full approval. The U.S. Food and Drug Administration (FDA) has granted full approval to selpercatinib (Retevmo) for patients 2...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now